Milestone Pharmaceuticals (MIST) Income from Continuing Operations (2018 - 2022)
Milestone Pharmaceuticals' (MIST) quarterly Income from Continuing Operations came in at 15030000.0 in Q3 2022, down 5.66% YoY from 15931576.01 in Q3 2021, and up 10.57% on a QoQ basis from 16806000.0 in Q2 2022.
Milestone Pharmaceuticals (MIST) Income from Continuing Operations (2018 - 2022) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 5 years of Income from Continuing Operations data on file, last reported at 15030000.0 in Q3 2022.
- Quarterly Income from Continuing Operations fell 5.66% year-over-year to 15030000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 62945000.0 (down 81.74% YoY) and the FY2021 annual result came in at 42853000.0, up 14.24% from the prior year.
- Income from Continuing Operations grew to 15030000.0 in Q3 2022, from 16806000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 770000.0 in Q2 2021 to a low of 18288000.0 in Q4 2019.
- A 5-year average of 11281777.78 and a median of 12672500.0 in 2019 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations soared 105.93% — and 2022, when it plunged 2282.6%.
- Tracing MIST's Income from Continuing Operations over 5 years: stood at 9717000.0 in 2018, then sank by 88.21% to 18288000.0 in 2019, then surged by 52.61% to 8666000.0 in 2020, then sank by 94.83% to 16884000.0 in 2021, then advanced by 10.98% to 15030000.0 in 2022.
- The last three Income from Continuing Operations figures came in at 15030000.0 (Q3 2022), 16806000.0 (Q2 2022), and 16884000.0 (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -15.03 Mn |
| Jun 30, 2022 | -16.81 Mn |
| Dec 31, 2021 | -16.88 Mn |
| Sep 30, 2021 | -14.23 Mn |
| Jun 30, 2021 | 770,000.00 |
| Mar 31, 2021 | -12.51 Mn |
| Dec 31, 2020 | -8.67 Mn |
| Sep 30, 2020 | -11.98 Mn |
| Jun 30, 2020 | -12.98 Mn |
| Mar 31, 2020 | -16.34 Mn |
| Dec 31, 2019 | -18.29 Mn |
| Sep 30, 2019 | -12.83 Mn |
| Jun 30, 2019 | -13.66 Mn |
| Mar 31, 2019 | -10.45 Mn |
| Dec 31, 2018 | -9.72 Mn |
| Sep 30, 2018 | -5.70 Mn |
| Jun 30, 2018 | -3.59 Mn |
| Mar 31, 2018 | -4.18 Mn |